Based on these findings, we believe that the existing immune suppression caused by the SPHK1-MMP1 axis could be reversed through anti-PD-1 mAb treatment, which manifests as the accumulation of tumor-infiltrating PD-1+CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.